secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001171843-26-000096
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Johns Hopkins Hospital treats first commercial TULSA-PRO case, expanding access to advanced prostate care
--------------------------------------------------------------------------------

- Johns Hopkins Hospital treated its first non-clinical-trial prostate cancer patient using Profound's TULSA-PRO system.
- Milestone coincides with the opening of Johns Hopkins Medicine's new interventional MRI suite.
- TULSA-PRO delivers robotically controlled directional ultrasound under real-time MRI thermography to ablate prostate tissue.
- Johns Hopkins was an early participant in the TACT and CAPTAIN trials that supported FDA clearance of TULSA-PRO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326000096/0001171843-26-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326000096/f8k_010626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer